FAX FORM TO: 1.877.597.3070

PHONE: 1.800.473.3516

EMAIL: specialty@wellpartner.com

Complete	the	following	or include	demographic sheet	

1. PATIENT INFORMATION	2. PRESCRIBER INFORMATION				
Name:	Name:				
Address:	DEA #:		NPI #:	State Lic. #:	
City, State, ZIP:	Group or Hospital:				
Primary Phone: DOB:	Address:				
Alternate Phone: Gender:	City, State, Zip:				
Email:	Phone: -	-	Fax:		
Primary Language: Last Four	Contact Perso	n:	Phon	e:	
3. INSURANCE INFORMATION	Fax copy of presc	ription and insu	rance cai	ds with this form, if a	vailable (front and back)
Primary Insurance Company Name:	Secondary Insurance Company Name:				
Primary Cardholder Name:	Secondary Cardholder Name:				
Relationship: 🔘 Self 🛛 Spouse/Partner 🤇) Child/Dependent	Relationship:	🔵 Self	Spouse/Partner	Child/Dependent
Phone: Member ID:	Group #:	Phone: -		Member ID:	Group #:
4. DIAGNOSIS AND CLINICAL INFORMATION					
Needs by Date: / /	Ship to: OPatient	Office	Other		
Date of Diagnosis: / / New York Heart Associati		ion (NYHA) functional classification: \bigcirc I \bigcirc II \bigcirc III \bigcirc IV			
I27.Ø Primary pulmonary hypertension	Is patient currently on another therapy for PAH? \bigcirc Yes \bigcirc No				
 I27.2 Other secondary pulmonary hypertension Secondary to: 	Nursing Not needed Pre-hospital/pre-home teaching In-hospital teaching Nursing follow-up				
Height (in/cm): Weight (lb/kg):	Start of care date: / / Number of visits:				

Allergies:

Current Medications:

5 DRESCRIPTION INFORMATION

Medication	Dose/Strength	Directions	Quantity	Refills
🔿 Adcirca (taladafil)	20 mg tablet	 Take two tablets (40 mg total) once daily. Other: 		
🔿 Revatio (sildenafil)	20 mg tablet	 Take one tablet 3 times daily. Other: 		
🔘 Revatio suspension 112 ml bottle	10 mg/ml suspension			
O Revatio	10 mg/12.5ml vial			
◯ Epoprostenol (LD)*	(LD)* These are limited dis	, stribution drugs that require additional handling. Please call (1.800.473.3	516) for more information.	
◯ Letairis (LD)*				
Opsumit (LD)*				
Orenitram (LD)*				
🔘 Remodulin (LD)*				
◯ Tracleer (LD)*				
◯ Tyvaso (LD)*				
◯ Uptravi (LD)*				
🔿 Veletri (LD)*				
Veletin(LD)				

supp ry

6. PRESCRIBER SIGNATURE								
х	/	/	x	/	/			
DISPENSE AS WRITTEN		DATE	PRODUCT SUBSTITUTION PERMITTED		DATE			

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address or telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee